These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26391562)

  • 21. Growth hormone tumor histological subtypes predict response to surgical and medical therapy.
    Kiseljak-Vassiliades K; Carlson NE; Borges MT; Kleinschmidt-DeMasters BK; Lillehei KO; Kerr JM; Wierman ME
    Endocrine; 2015 May; 49(1):231-41. PubMed ID: 25129651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo.
    Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Olsen N; Bojsen-Møller M; Astrup J; Weeke J; Jørgensen JO
    J Endocrinol Invest; 2001 Jun; 24(6):430-7. PubMed ID: 11434667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies.
    Chinezu L; Vasiljevic A; Jouanneau E; François P; Borda A; Trouillas J; Raverot G
    Hum Pathol; 2014 Jan; 45(1):71-7. PubMed ID: 24182563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.
    Shimon I
    Endocrine; 2003 Apr; 20(3):265-9. PubMed ID: 12721506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors.
    Peverelli E; Giardino E; Treppiedi D; Meregalli M; Belicchi M; Vaira V; Corbetta S; Verdelli C; Verrua E; Serban AL; Locatelli M; Carrabba G; Gaudenzi G; Malchiodi E; Cassinelli L; Lania AG; Ferrero S; Bosari S; Vitale G; Torrente Y; Spada A; Mantovani G
    Int J Cancer; 2017 Apr; 140(8):1870-1880. PubMed ID: 28120505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
    Pisarek H; Pawlikowski M; Kunert-Radek J; Winczyk K
    Endokrynol Pol; 2010; 61(2):178-81. PubMed ID: 20464704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.
    Zatelli MC; Piccin D; Tagliati F; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Culler MD; degli Uberti EC
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2797-802. PubMed ID: 12788890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro.
    Tulipano G; Bonfanti C; Milani G; Billeci B; Bollati A; Cozzi R; Maira G; Murphy WA; Poiesi C; Turazzi S; Giustina A
    Neuroendocrinology; 2001 May; 73(5):344-51. PubMed ID: 11399907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.
    Shimon I; Taylor JE; Dong JZ; Bitonte RA; Kim S; Morgan B; Coy DH; Culler MD; Melmed S
    J Clin Invest; 1997 Feb; 99(4):789-98. PubMed ID: 9045884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.
    Casarini AP; Pinto EM; Jallad RS; Giorgi RR; Giannella-Neto D; Bronstein MD
    J Endocrinol Invest; 2006 Oct; 29(9):826-30. PubMed ID: 17114915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas.
    Taboada GF; Neto LV; Luque RM; Córdoba-Chacón J; de Oliveira Machado E; de Carvalho DP; Kineman RD; Gadelha MR
    Neuroendocrinology; 2011; 93(1):40-7. PubMed ID: 21079388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
    Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
    Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E-cadherin expression and gene expression profiles in corticotroph pituitary neuroendocrine tumor subtypes.
    Kiseljak-Vassiliades K; Lipe K; Turin CG; Fishbein L; Costello JC; Kerr JM; Holmstoen TB; Youssef AS; Lillehei KO; Kleinschmidt-DeMasters BK; Wierman ME
    J Neuropathol Exp Neurol; 2024 Jun; 83(7):586-595. PubMed ID: 38777808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
    Peverelli E; Giardino E; Mangili F; Treppiedi D; Catalano R; Ferrante E; Sala E; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
    Cancer Lett; 2018 Oct; 435():101-109. PubMed ID: 30098401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly.
    Soukup J; Hornychova H; Manethova M; Michalova K; Michnova L; Popovska L; Skarkova V; Cesak T; Netuka D; Ryska A; Cap J; Hána V; Hána V; Kršek M; Dvořáková E; Krčma M; Lazurova I; Olšovská V; Starý K; Vaňuga P; Gabalec F
    J Cell Mol Med; 2021 Mar; 25(5):2484-2492. PubMed ID: 33491286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PREDICTIVE MARKERS FOR POSTSURGICAL MEDICAL MANAGEMENT OF ACROMEGALY: A SYSTEMATIC REVIEW AND CONSENSUS TREATMENT GUIDELINE.
    Ezzat S; Caspar-Bell GM; Chik CL; Denis MC; Domingue MÈ; Imran SA; Johnson MD; Lochnan HA; Grégoire Nyomba BL; Prebtani A; Ridout R; Ramirez JAR; Van Uum S
    Endocr Pract; 2019 Apr; 25(4):379-393. PubMed ID: 30657362
    [No Abstract]   [Full Text] [Related]  

  • 37. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
    Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.
    Ramírez C; Cheng S; Vargas G; Asa SL; Ezzat S; González B; Cabrera L; Guinto G; Mercado M
    J Clin Endocrinol Metab; 2012 May; 97(5):1745-51. PubMed ID: 22419713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology.
    Kumar U; Grigorakis SI; Watt HL; Sasi R; Snell L; Watson P; Chaudhari S
    Breast Cancer Res Treat; 2005 Jul; 92(2):175-86. PubMed ID: 15986128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors.
    Panetta R; Patel YC
    Life Sci; 1995; 56(5):333-42. PubMed ID: 7530798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.